Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2023
Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell TumorsJennifer M King, Michael Cheng, Kenneth Kesler, et al.
Clinical Genitourinary Cancer|April 23, 2023
Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-onlyNoah H Richardson, Sandra K Althouse, Ryan Ashkar, et al.
Cancer Medicine|February 6, 2025
Prediction Model for Brain Metastasis in Patients With Metastatic Germ-Cell TumorsTareq Salous, Ryan Ashkar, Sandra K Althouse, et al.
Cancer|July 14, 2021
Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantationVaibhav Agrawal, Rafat Abonour, Mohammad Abu Zaid, et al.
The Journal of Urology|June 8, 2022
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell TumorJennifer M King, Sandra Althouse, Clint Cary, et al.
Cancer|May 20, 2024
High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experienceNoah H Richardson, Fadi Taza, Rafat Abonour, et al.
Investigational New Drugs|May 25, 2021
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumorsRyan Ashkar, Darren R Feldman, Nabil Adra, et al.
The Oncologist|November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate CancerLaura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Pageof 2